Dendritic Cell Biology and Immune Response Modulation

Dendritic cells (DCs) are professional antigen-presenting cells that bridge innate detection of pathogens and the activation of adaptive immunity. Arising from bone-marrow progenitors under the influence of growth factors such as FLT3 ligand, DCs differentiate into specialised subsets including conventional type 1 DCs (cDC1), conventional type 2 DCs (cDC2) and plasmacytoid DCs (pDC). Each subset possesses distinct transcriptional programmes and surface receptors that dictate migratory patterns, cytokine production and the capacity to prime CD8+ or CD4+ T cells. Through cross-presentation of exogenous antigens on MHC class I molecules, cDC1s are central to anti-viral and anti-tumour cytotoxic responses, whereas cDC2s excel at driving helper T cell differentiation. pDCs rapidly secrete type I interferons in response to viral nucleic acids. Tissue-resident DCs maintain local immune surveillance, while monocyte-derived DCs emerge during inflammation. Modulation of DC activation and maturation underpins vaccine design, tolerance induction and cancer immunotherapy. Advances in genetic engineering, adjuvant formulation and subset-specific targeting have demonstrated that tailored DC interventions can enhance protective immunity against infection and malignancy, while also tempering autoimmune or allergic responses.

Research from Nature Portfolio

Innovative work has established a blueprint for engineering DC vaccines that couple subset-specific targeting with molecular enhancement of antigen processing. By genetically modifying DC precursors to overexpress key endosomal sorting receptors and cytokine-inducing transcription factors, researchers have achieved superior loading of tumour neoantigens onto MHC molecules and amplified co-stimulatory signal expression. In preclinical models, these optimised vaccines elicit robust CD8+ T cell expansion, durable memory responses and improved control of established tumours. Early translational efforts demonstrate safety and heightened immunogenicity in patients, marking a significant step towards personalised cellular immunotherapy.

Dendritic Cell Biology and Immune Response Modulation publication trend

The graph below shows the total number of articles in dendritic cell biology and immune response modulation across all publications each year (not limited to Nature Index journals).

Technical terms

Cross-presentation: the display of extracellular antigens on MHC class I molecules for activation of CD8+ T cells.

cDC1: a dendritic cell subset specialised in uptake of dead-cell antigens and priming of cytotoxic T cells through cross-presentation.

FLT3 ligand (FLT3L): a haematopoietic growth factor essential for the development and maintenance of dendritic cells and B cells.

Transcriptomic profiling: genome-wide measurement of RNA expression used to classify cell types and functional states.

References

1. Dendritic Cells Revisited. Annual Review of Immunology (2021).
2. Engineering dendritic cell vaccines to improve cancer immunotherapy. Nature Communications (2019).
3. FLT3L governs the development of partially overlapping hematopoietic lineages in humans and mice. Cell (2024).
4. Transcriptional Basis of Mouse and Human Dendritic Cell Heterogeneity. Cell (2019).